库欣病的肿瘤靶向治疗靶点
库欣病是内源性高皮质醇血症最常见的原因,与严重并发症和高死亡率相关,而有效的肿瘤靶向治疗有限。该综述通过检索PubMed和ClinicalTrials.gov,总结当前肿瘤靶向药物治疗集中于多巴胺激动剂(卡麦角林)和生长抑素类似物(帕瑞肽),疗效不一、存在逃逸和显著副作用。临床前研究提示维A酸、水飞蓟宾和roscovitine等潜在药物,但疗效和安全性待确定。
要点
- 当前肿瘤靶向药物主要为卡麦角林和帕瑞肽,疗效不一且可能逃逸。
- 维A酸、水飞蓟宾和roscovitine等临床前药物疗效安全性待确定。
- 许多库欣病患者仍缺乏有效的肿瘤靶向药物治疗。
核心结论
- 许多库欣病患者仍缺乏有效的肿瘤靶向药物治疗。
- 协调努力对确立新型治疗在罕见但破坏性疾病中的疗效和安全性至关重要。
研究设计与样本
- 通过PubMed检索关键词「corticotroph」和「Cushing's disease」加上提及的治疗药物名称及相关参考文献。
- 从ClinicalTrials.gov检索「Cushing disease」获取潜在治疗药物。
主要发现
- 当前肿瘤靶向药物治疗集中于多巴胺激动剂(卡麦角林)和生长抑素类似物(帕瑞肽),疗效不一、存在反应逃逸和显著副作用。
- 临床前研究提示维A酸、水飞蓟宾和roscovitine等潜在药物,疗效和安全性待确定。
临床怎么用
- 对于库欣病患者,可考虑使用卡麦角林或帕瑞肽进行肿瘤靶向药物治疗,但需注意疗效不一、反应逃逸和副作用。
局限性
- 维A酸、水飞蓟宾和roscovitine等潜在药物的疗效和安全性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The most frequent cause of endogenous hypercortisolism is Cushing disease (CD), a devastating condition associated with severe comorbidities and high mortality. Effective tumor-targeting therapeutics are limited. DESIGN: Search in PubMed with key words "corticotroph" and "Cushing's disease" plus the name of the mentioned therapeutic agent and in associated references of the obtained papers. Additionally, potential therapeutics were obtained from ClinicalTrials.gov with a search for "Cushing disease." RESULTS: At present, the tumor-targeted pharmacological therapy of CD is concentrated on dopamine agonists (cabergoline) and somatostatin analogs (pasireotide) with varying efficacy, escape from response, and considerable side effects. Preclinical studies on corticotroph pathophysiology have brought forward potential drugs such as retinoic acid, silibinin, and roscovitine, whose efficacy and safety remain to be determined. CONCLUSIONS: For many patients with CD, effective tumor-targeted pharmacological therapy is still lacking. Coordinated efforts are pivotal in establishing efficacy and safety of novel therapeutics in this rare but devastating disease.
引用
- Theodoropoulou M, Reincke M. Tumor-Directed Therapeutic Targets in Cushing Disease. J Clin Endocrinol Metab. 2019. PMID: 30535260. doi:10.1210/jc.2018-02080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。